Who is at higher risk for INH-induced hepatotoxicity?

Individuals over 35 years old are considered to be at higher risk for isoniazid (INH)-induced hepatotoxicity due to several factors related to age. As people age, their liver function may decline, which can impair the metabolism and clearance of medications, leading to an increased likelihood of drug-induced liver damage. Older adults may also be more susceptible to the effects of hepatotoxic substances because of differences in liver enzyme activity and overall health status, including the presence of comorbidities.

In addition, age-related factors such as pre-existing liver conditions and the cumulative effect of long-term medication use can contribute further to this risk. Although individuals with diabetes also face some risk due to associated health complications, age remains a more significant predictive factor for hepatotoxicity in the context of INH usage.

Other demographic factors, like smoking status or being under a certain age, do not show the same direct correlation with increased risk for hepatotoxicity when compared to age. Therefore, those over 35 years old are more critically monitored for any signs of liver injury while undergoing treatment with INH.